Article
Oncology
David H. Johnson, Louis Fehrenbacher, William F. Novotny, Roy S. Herbst, John J. Nemunaitis, David M. Jablons, Corey J. Langer, Russell F. DeVore III, Jacques Gaudreault, Lisa A. Damico, Eric Holmgren, Fairooz Kabbinavar
Summary: This study aimed to investigate the efficacy and safety of bevacizumab in combination with carboplatin and paclitaxel for advanced or recurrent non-small-cell lung cancer. The results showed that the addition of bevacizumab improved overall response and time to progression, but bleeding was the most prominent adverse event. Patients with nonsquamous cell histology appeared to have better treatment outcomes and acceptable safety risks.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Genetics & Heredity
Seung Tae Kim, Jason K. Sa, Sung Yong Oh, Kyung Kim, Jung Yong Hong, Won Ki Kang, Kyoung-Mee Kim, Jeeyun Lee
Summary: The study identified a subset of GC patients with distinct clinical response to ramucirumab therapy through prospective molecular characterization. The results demonstrate the feasibility of personalized therapeutic opportunities in gastric cancer.
Article
Biochemistry & Molecular Biology
Helena Branco, Julio Oliveira, Catarina Antunes, Lucio L. Santos, Maria Helena Vasconcelos, Cristina P. R. Xavier
Summary: This study investigated the potential of using Pirfenidone to enhance the sensitivity of non-small cell lung cancer (NSCLC) cells to chemotherapy. The results showed that Pirfenidone increased the effectiveness of paclitaxel treatment on NSCLC cells without increasing toxicity in non-tumorigenic cells. This research suggests the possibility of repurposing Pirfenidone in combination with chemotherapy for treating NSCLC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Corey J. Langer, Ajeet Gajra, Cesare Gridelli, Kartik Konduri, Daniel Morgensztern, David Spigel, Denis Talbot, Michael Thomas, Jared Weiss, Richard Pilot, Rafia Bhore, Marianne Wolfsteiner, Teng Jin Ong, Mark Socinski
Summary: Despite the underrepresentation of certain patient populations in clinical trials for advanced NSCLC, a pooled analysis of elderly patients and those with renal impairment, diabetes, or poor performance status showed varying but promising outcomes, supporting the use of nab-paclitaxel-based regimens in these historically understudied and vulnerable populations.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Rosalba D'Alessandro, Maria Grazia Refolo, Annalisa Schirizzi, Giampiero De Leonardis, Rossella Donghia, Vito Guerra, Gianluigi Giannelli, Ivan Roberto Lolli, Maria Maddalena Laterza, Ferdinando De Vita, Caterina Messa, Claudio Lotesoriere
Summary: The combination therapy of paclitaxel and ramucirumab is the preferred treatment for advanced gastric cancer. However, there are currently no biomarkers available to predict the outcome of antiangiogenic therapy in gastric cancer. This study found that monitoring the changes in VEGFC and Angiopoietin-2 levels during second-line therapy can help predict patient progression.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
I. Vergote, E. Van Nieuwenhuysen, A. Casado, A. Laenen, D. Lorusso, E. I. Braicu, E. Guerra-Alia, P. Zola, P. Wimberger, P. R. Debruyne, E. Falco, A. Ferrero, M. Z. Muallem, J. Kerger, E. Garcia-Martinez, S. Pignata, J. Sehouli, T. Van Gorp, C. Gennigens, M. J. Rubio
Summary: This study aimed to establish the role of nintedanib in first-line recurrent/metastatic cervical cancer. The results showed that nintedanib improved the progression-free survival compared to the carboplatin-paclitaxel group. The nintedanib group had a longer median overall survival and a higher RECIST response rate.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Oncology
Chang Gon Kim, Minkyu Jung, Hyo Song Kim, Choong-kun Lee, Hei-Cheul Jeung, Dong-Hoe Koo, Woo Kyun Bae, Dae Young Zang, Bum Jun Kim, Hyunki Kim, Un-Jung Yun, Jingmin Che, Sejung Park, Tae Soo Kim, Woo Sun Kwon, Juin Park, Sang Woo Cho, Chung Mo Nam, Hyun Cheol Chung, Sun Young Rha
Summary: Trastuzumab combined with ramucirumab and paclitaxel showed appreciable efficacy with manageable safety profiles in patients with previously treated HER2-positive G/GEJ cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Wen-Chien Cheng, Yi-Cheng Shen, Chieh-Lung Chen, Wei-Chih Liao, Chia-Hung Chen, Hung-Jen Chen, Chih-Yen Tu, Te-Chun Hsia
Summary: The addition of bevacizumab or ramucirumab to systemic therapy for EGFR-mutated non-small-cell lung cancer patients provides survival benefits. This study compared the efficacy and safety of these two antiangiogenic therapies and found that they were similar in terms of progression-free survival and overall survival. The effectiveness and safety of the two therapies were similar.
Article
Oncology
Lorenzo Fornaro, Gianna Musettini, Paola Orlandi, Irene Pecora, Caterina Vivaldi, Marta Banchi, Francesca Salani, Elisabetta Fini, Valentina Massa, Silvia Catanese, Federico Cucchiara, Monica Lencioni, Gianluca Masi, Enrico Vasile, Guido Bocci
Summary: Ramucirumab plus paclitaxel is considered standard treatment for second-line gastric carcinoma (GC) patients. This study evaluated plasma VEGF-A, VEGF-D, and sVEGFR-2 as potential markers of resistance or response to this treatment. Results showed significant increases in VEGF-A and VEGF-D levels during treatment, and early increase in sVEGFR-2 levels was associated with longer progression-free survival and overall survival.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Article
Oncology
Annalisa Schirizzi, Marialessandra Contino, Livianna Carrieri, Chiara Riganti, Giampiero De Leonardis, Maria Principia Scavo, Maria Grazia Perrone, Morena Miciaccia, Joanna Kopecka, Maria Grazia Refolo, Claudio Lotesoriere, Nicoletta Depalo, Federica Rizzi, Gianluigi Giannelli, Caterina Messa, Rosalba D'Alessandro
Summary: This study aimed to investigate the molecular processes underlying PTX-mediated resistance in gastric cancer cells. The key features of PTX-resistant cells were found to be the overexpression of pro-angiogenic factors and the elevated level of TUB beta III and P-glycoprotein. The findings also highlighted the effectiveness of Ramucirumab and Elacridar in treating resistant cells.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
S. Sugawara, J-S Lee, J-H Kang, H. R. Kim, N. Inui, T. Hida, K. H. Lee, T. Yoshida, H. Tanaka, C-T Yang, M. Nishio, Y. Ohe, T. Tamura, N. Yamamoto, C-J Yu, H. Akamatsu, Y. Namba, N. Sumiyoshi, K. Nakagawa
Summary: This international study evaluated nivolumab with bevacizumab and chemotherapy as a first-line treatment for nonsquamous NSCLC, showing significantly longer progression-free survival and higher objective response rates in the nivolumab group compared to the placebo group in the interim analysis. The incidence of severe treatment-related adverse events was comparable between the two groups.
ANNALS OF ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Michiel S. van der Heijden, Thomas Powles, Daniel Petrylak, Ronald de Wit, Andrea Necchi, Cora N. Sternberg, Nobuaki Matsubara, Hiroyuki Nishiyama, Daniel Castellano, Syed A. Hussain, Aristotelis Bamias, Georgios Gakis, Jae-Lyun Lee, Scott T. Tagawa, Ulka Vaishampayan, Jeanny B. Aragon-Ching, Bernie J. Eigl, Rebecca R. Hozak, Erik R. Rasmussen, Meng Summer Xia, Ryan Rhodes, Sameera Wijayawardana, Katherine M. Bell-McGuinn, Amit Aggarwal, Alexandra Drakaki
Summary: This study identifies potential predictive biomarkers for survival benefit in patients with platinum-refractory advanced urothelial carcinoma treated with the anti-VEGFR2 monoclonal antibody ramucirumab. Higher PD-L1 IHC and immune pathway scores are associated with greater ramucirumab overall survival (OS) benefit. Basal molecular subtypes show greater OS benefit compared to Luminal subtypes. Patients from East Asia have lower immune/angiogenesis signature scores, correlating with decreased ramucirumab OS benefit. The study highlights the importance of multiple biomarkers in identifying patients who might benefit the most from treatment with ramucirumab.
NATURE COMMUNICATIONS
(2022)
Article
Oncology
Toshinobu Hayashi, Mototsugu Shimokawa, Koichi Matsuo, Hirotoshi Iihara, Kei Kawada, Takafumi Nakano, Takashi Egawa
Summary: Patients with lung cancer undergoing carboplatin plus pemetrexed (CBDCA+PEM) chemotherapy have a higher risk of delayed nausea compared to those undergoing carboplatin plus paclitaxel (CBDCA+PTX) chemotherapy, while the incidence of vomiting does not significantly differ between the two groups. Female sex, younger age, and CBDCA+PEM regimen are independent risk factors for delayed nausea, while female sex is an independent risk factor for delayed vomiting.
Article
Medicine, General & Internal
Yin Tao, Xue-Ting Tang, Xing Li, An-Shan Wu, Hou-Shen Zhou, Cheng-fang Zhou
Summary: This study evaluated the role of neoadjuvant chemotherapy (NACT) with intraperitoneal perfusion of bevacizumab in advanced ovarian cancer. The results showed that treatment with the TCB regimen significantly reduced serum levels of CA125 and ascites volume, as well as intraoperative blood loss and operation time. Patients treated with the TCB regimen had a higher surgical satisfaction rate, and a lower incidence of postoperative complications compared with the TC group. No severe complications were observed between the two groups during chemotherapy.
FRONTIERS IN MEDICINE
(2022)
Article
Oncology
Naoya Ikeda, Ryo Arai, Sayo Soda, Takashi Inoue, Nobuhiko Uchida, Yusuke Nakamura, Meitetsu Masawa, Yoshitomo Kushima, Hiroaki Okutomi, Akihiro Takemasa, Yasuo Shimizu, Seiji Niho
Summary: This study aimed to evaluate the efficacy of carboplatin plus nab-paclitaxel in the treatment of recurrent small cell lung cancer (SCLC). The overall response rate was 19.0%, and the median progression-free survival time and median survival time were 2.5 and 5.1 months, respectively. However, two patients developed serious interstitial lung disease. In conclusion, this combination chemotherapy has modest activity for recurrent SCLC, but further investigation is needed.
Review
Immunology
Gabriel Osborn, Chara Stavraka, Rebecca Adams, Ahmad Sayasneh, Sharmistha Ghosh, Ana Montes, Katie E. Lacy, Rebecca Kristeleit, James Spicer, Debra H. Josephs, James N. Arnold, Sophia N. Karagiannis
Summary: This review discusses the role of tumor-associated macrophages (TAMs) in the ovarian cancer tumor microenvironment (TME) and the emerging strategies that target the contributions of these cells in tumor progression through the rational design of monoclonal antibodies (mAbs).
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
(2022)
Article
Immunology
Panagiotis Karagiannis, Isabel Correa, Jitesh Chauhan, Anthony Cheung, Diana Dominguez-Rodriguez, Manuela Terranova-Barberio, Robert J. Harris, Silvia Crescioli, James Spicer, Carsten Bokemeyer, Katie E. Lacy, Sophia N. Karagiannis
Summary: The study found that innate signals can stimulate the survival and antibody production of B cells, which may help identify low-frequency antigen-reactive humoral responses.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
(2022)
Article
Medicine, Research & Experimental
Varsha Ananthapadmanabhan, Thomas C. Frost, Kara M. Soroko, Aine Knott, Brianna J. Magliozzi, Prafulla C. Gokhale, Vijaya G. Tirunagaru, Robert C. Doebele, James A. DeCaprio
Summary: In this study, the efficacy of milademetan, an MDM2 inhibitor, was assessed in various MCC models, showing significant inhibition on WT p53 MCC tumors. Useful in vitro and in vivo models for future MCC studies were also reported.
Article
Oncology
Heather J. Bax, Jitesh Chauhan, Chara Stavraka, Aida Santaolalla, Gabriel Osborn, Atousa Khiabany, Melanie Grandits, Jacobo Lopez-Abente, Lais C. G. F. Palhares, Charleen Chan Wah Hak, Alexandra Robinson, Amy Pope, Natalie Woodman, Cristina Naceur-Lombardelli, Sadek Malas, Jack E. M. Coumbe, Mano Nakamura, Roman Laddach, Silvia Mele, Silvia Crescioli, Anna M. Black, Sara Lombardi, Silvana Canevari, Mariangela Figini, Ahmad Sayasneh, Sophia Tsoka, Kevin FitzGerald, Cheryl Gillett, Sarah Pinder, Mieke Van Hemelrijck, Rebecca Kristeleit, Sharmistha Ghosh, Ana Montes, James Spicer, Sophia N. Karagiannis, Debra H. Josephs
Summary: This study investigated the potential use of sFR alpha as a biomarker for ovarian cancer. The results showed that sFR alpha levels were significantly higher in patients compared to healthy volunteers and decreased alongside tumor burden during treatment. Additionally, high concentrations of sFR alpha reduced the effectiveness of anti-FR alpha antibodies, but this effect could be overcome by increasing antibody doses.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Charu Aggarwal, Nabil F. Saba, Alain Algazi, Ammar Sukari, Tanguy Y. Seiwert, Missak Haigentz, Mercedes Porosnicu, Marcelo Bonomi, Jean Boyer, Mark T. Esser, Lily I. Cheng, Sonia Agrawal, Emily C. Jennings, Nicholas M. Durham, Karl Fraser, Delphine Lissa, Maozhen Gong, Natalia Ceaicovscaia, Amaya Gasco Hernandez, Rakesh Kumar
Summary: The study investigated the efficacy of a DNA vaccine targeting HPV-16/18 E6/E7 combined with the PD-L1 inhibitor durvalumab in HPV-associated head and neck squamous cell carcinoma. The results showed enhanced HPV-specific T-cell response and improved outcomes in recurrent/metastatic HPV-16/18-associated HNSCC.
CLINICAL CANCER RESEARCH
(2023)
Editorial Material
Immunology
Ammara Masood, Amanda Mootoo, Panayiotis Maghsoudlou, David D'Cruz, Krishnie Srikandarajah, Mark Harries, Nicholas Hart, Sophie Papa, James Spicer
AUTOIMMUNITY REVIEWS
(2023)
Article
Oncology
Cienne Morton, Richard Sullivan, Debashis Sarker, John Posner, James Spicer
Summary: The COVID-19 pandemic has posed a significant threat to cancer patients, impacting their standard care and disrupting clinical trials. However, it has also provided an opportunity for positive reforms in clinical cancer research, as the lessons learned from streamlining processes during the pandemic can be applied to improve the traditionally complex approval, trial design, procedures, and data collection in cancer research.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Matthew P. Deek, Missak Haigentz, Salma K. Jabbour
Summary: The article summarizes the Oncology Grand Rounds series, which aims to provide clinical context to original reports published in the Journal. It includes a case presentation, description of diagnostic and management challenges, literature review, and suggested management approaches. The goal is to help readers understand how to apply key study results to their own clinical practice.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Silvia Crescioli, Isabel Correa, Joseph Ng, Zena N. Willsmore, Roman Laddach, Alicia Chenoweth, Jitesh Chauhan, Ashley Di Meo, Alexander Stewart, Eleni Kalliolia, Elena Alberts, Rebecca Adams, Robert J. Harris, Silvia Mele, Giulia Pellizzari, Anna B. M. Black, Heather J. Bax, Anthony Cheung, Mano Nakamura, Ricarda M. Hoffmann, Manuela Terranova-Barberio, Niwa Ali, Ihor Batruch, Antoninus Soosaipillai, Ioannis Prassas, Antigona Ulndreaj, Miyo K. Chatanaka, Rosamund Nuamah, Shichina Kannambath, Pawan Dhami, Jenny L. C. Geh, Alastair D. MacKenzie Ross, Ciaran Healy, Anita Grigoriadis, David Kipling, Panagiotis Karagiannis, Deborah K. Dunn-Walters, Eleftherios P. Diamandis, Sophia Tsoka, James Spicer, Katie E. Lacy, Franca Fraternali, Sophia N. Karagiannis
Summary: B cells play an important role in the anti-tumor immune response in immunogenic tumors such as melanoma. Tumor-associated B cells undergo clonal expansion, class switch recombination, somatic hypermutation, and receptor revision. Tumor-associated B cells produce antibodies with higher levels of unproductive sequences and distinct complementarity determining region 3 properties. These findings suggest the presence of an active and aberrant autoimmune-like reaction in the tumor microenvironment.
NATURE COMMUNICATIONS
(2023)
Article
Multidisciplinary Sciences
Jitesh Chauhan, Melanie Grandits, Lais C. G. F. Palhares, Silvia Mele, Mano Nakamura, Jacobo Lopez-Abente, Silvia Crescioli, Roman Laddach, Pablo Romero-Clavijo, Anthony Cheung, Chara Stavraka, Alicia M. M. Chenoweth, Heng Sheng Sow, Giulia Chiaruttini, Amy E. E. Gilbert, Tihomir Dodev, Alexander Koers, Giulia Pellizzari, Kristina M. M. Ilieva, Francis Man, Niwa Ali, Carl Hobbs, Sara Lombardi, Daniel A. Lionarons, Hannah J. J. Gould, Andrew J. J. Beavil, Jenny L. C. Geh, Alastair D. MacKenzie D. Ross, Ciaran Healy, Eduardo Calonje, Julian Downward, Frank O. O. Nestle, Sophia Tsoka, Debra H. H. Josephs, Philip J. J. Blower, Panagiotis Karagiannis, Katie E. E. Lacy, James Spicer, Sophia N. N. Karagiannis, Heather J. J. Bax
Summary: Despite checkpoint inhibitor therapies, outcomes for 50% of melanoma patients remain poor. Melanoma-associated antigen CSPG4 is expressed in approximately 70% of cases, making it a potential target for effective immunotherapies. Using monoclonal IgE antibodies engineered with human constant domains to recognize CSPG4, we found that IgE binds to human melanomas, induces antibody-dependent cellular cytotoxicity, and stimulates pro-inflammatory responses in Fc-receptor-expressing monocytes. IgE demonstrates anti-tumor activity in melanoma xenograft models, enhancing macrophage infiltration and pro-inflammatory signaling pathways in the tumor microenvironment. Our findings suggest that IgE-based immunotherapy holds promise for melanoma treatment.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Sophie Papa, Antonella Adami, Michael Metoudi, Richard Beatson, Molly Sarah George, Daniela Achkova, Evangelia Williams, Sefina Arif, Fiona Reid, Maria Elstad, Nicholas Beckley-Hoelscher, Abdel Douri, Marc Delord, Mike Lyne, Dharshene Shivapatham, Christopher Fisher, Andrew Hope, Sakina Gooljar, Arindam Mitra, Linda Gomm, Cienne Morton, Rhonda Henley-Smith, Selvam Thavaraj, Alice Santambrogio, Cynthia Andoniadou, Sarah Allen, Victoria Gibson, Gary J. R. Cook, Ana C. Parente-Pereira, David M. Davies, Farzin Farzaneh, Anna Schurich, Teresa Guerrero-Urbano, Jean-Pierre Jeannon, James Spicer, John Maher
Summary: This study developed an autologous CD28-based chimeric antigen receptor T-cell (CAR-T) therapy named T4 immunotherapy for locally advanced/recurrent head and neck squamous cell carcinoma (HNSCC). Patient-derived T-cells were engineered to express a panErbB-specific CAR and an IL-4-responsive chimeric cytokine receptor. Intratumoral delivery was used to mitigate off-tumor toxicity. The study demonstrated the safe and effective intratumoral administration of T4 immunotherapy in advanced HNSCC.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Multidisciplinary Sciences
James Spicer, Bristi Basu, Ana Montes, Udai Banerji, Rebecca Kristeleit, Rowan Miller, Gareth J. J. Veal, Christopher J. J. Corrigan, Stephen J. J. Till, Mariangela Figini, Silvana Canevari, Claire Barton, Paul Jones, Sarah Mellor, Simon Carroll, Chris Selkirk, George Nintos, Vineet Kwatra, Ionut-Gabriel Funingana, Gary Doherty, Hannah J. J. Gould, Giulia Pellizzari, Mano Nakamura, Kristina M. M. Ilieva, Atousa Khiabany, Chara Stavraka, Jitesh Chauhan, Cheryl Gillett, Sarah Pinder, Heather J. J. Bax, Debra H. H. Josephs, Sophia N. N. Karagiannis
Summary: The study reports the results of a phase I dose escalation trial of MOv18 IgE, a chimeric first-in-class IgE antibody, in patients with tumours expressing folate receptor-alpha. The most common toxicity observed was transient urticaria and evidence of anti-tumour activity was observed in a patient with ovarian cancer.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Ehsan Ghorani, Matteo Quartagno, Fiona Blackhall, Duncan C. Gilbert, Mary O'Brien, Christian Ottensmeier, Elena Pizzo, James Spicer, Alex Williams, Philip Badman, Mahesh K. B. Parmar, Michael J. Seckl
Summary: Some immunotherapy dosing regimens for advanced cancer patients may result in overtreatment, and new approaches are needed to reduce unnecessary treatment. REFINE-Lung is a UK multicentre phase 3 study that uses a novel design to determine the optimal dose frequency of pembrolizumab.
Article
Oncology
Hedy L. Kindler, Silvia Novello, Alessandra Bearz, Giovanni L. Ceresoli, Joachim G. J. Aerts, James Spicer, Paul Taylor, Kristiaan Nackaerts, Alastair Greystoke, Ross Jennens, Luana Calabro, Jacobus A. Burgers, Armando Santoro, Susana Cedres, Piotr Serwatowski, Santiago Ponce, Jan P. Van Meerbeeck, Anna K. Nowak, George Biumenschein, Jonathan M. Siegel, Linda Kasten, Karl Koechert, Annette O. Walter, Barrett H. Childs, Cem Elbi, Raffit Hassan, Dean A. Fennell
Summary: In second-line treatment of malignant pleural mesothelioma, the antibody-drug conjugate anetumab ravtansine showed similar safety and no superiority compared to vinorelbine.
Article
Oncology
Giuseppe Luigi Banna, Alfredo Addeo, Panagiota Zygoura, Zoi Tsourti, Sanjay Popat, Alessandra Curioni-Fontecedro, Ernest Nadal, Riyaz Shah, Anthony Pope, Patricia Fisher, James Spicer, Amy Roy, David Gilligan, Oliver Gautschi, Wolf-Dieter Janthur, Rafael Lopez-Castro, Heidi Roschitzki-Voser, Urania Dafni, Solange Peters, Rolf A. Stahel
Summary: This study aimed to identify clinical and laboratory parameters associated with treatment response in patients with relapsed MPM. The results showed that high SII and low hemoglobin levels were associated with worse progression-free survival. A mesothelioma risk score based on these two factors was constructed to stratify patients' prognosis.